An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 10 May 2017
At a glance
- Drugs PRX 106 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors Protalix Biotherapeutics
- 07 Jun 2017 Biomarkers information updated
- 10 May 2017 According to a Protalix BioTherapeutics media release, the company expects full results from this trial around the end of 2017..
- 05 Dec 2016 According to a Protalix BioTherapeutics media release, the company will announce data from this study in the second half of 2017.